Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 11,939,000 | 9,119,000 | 5,934,000 | 2,688,000 | 8,572,000 |
| Depreciation Amortization | 6,114,000 | 4,454,000 | N/A | 1,342,000 | 8,383,000 |
| Income taxes - deferred | 1,701,000 | 1,236,000 | N/A | 441,000 | 551,000 |
| Accounts receivable | -931,000 | -1,093,000 | -1,421,000 | -920,000 | -1,504,000 |
| Accounts payable and accrued liabilities | -105,000 | -660,000 | -551,000 | -409,000 | 479,000 |
| Other Working Capital | -706,000 | -711,000 | -1,751,000 | -1,989,000 | -369,000 |
| Other Operating Activity | -393,000 | 1,081,000 | 4,929,000 | 1,112,000 | -1,654,000 |
| Operating Cash Flow | $17,619,000 | $13,426,000 | $7,140,000 | $2,265,000 | $14,458,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -711,000 | 986,000 | 696,000 | 503,000 | 10,607,000 |
| PPE Investments | -1,280,000 | -769,000 | -449,000 | -226,000 | -823,000 |
| Net Acquisitions | -3,911,000 | -3,657,000 | -3,598,000 | -263,000 | -4,681,000 |
| Purchase Of Investment | -193,000 | -145,000 | -88,000 | -47,000 | -117,000 |
| Sale Of Investment | 957,000 | 936,000 | 710,000 | 63,000 | 348,000 |
| Purchase Sale Intangibles | -2,368,000 | -1,832,000 | -1,377,000 | -929,000 | 262,000 |
| Other Investing Activity | -2,375,000 | -1,831,000 | -1,377,000 | -929,000 | 262,000 |
| Investing Cash Flow | $-7,513,000 | $-4,480,000 | $-4,106,000 | $-899,000 | $5,596,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 958,000 | 982,000 | 1,789,000 | 1,220,000 | 546,000 |
| Debt Issued | 6,143,000 | 6,143,000 | 2,473,000 | N/A | N/A |
| Debt Repayment | -289,000 | -2,150,000 | N/A | N/A | -2,223,000 |
| Common Stock Issued | 30,000 | 30,000 | 25,000 | N/A | 153,000 |
| Common Stock Repurchased | -8,331,000 | -5,569,000 | -2,715,000 | -1,099,000 | -8,719,000 |
| Dividend Paid | -7,624,000 | -7,624,000 | -7,624,000 | -5,207,000 | -7,255,000 |
| Other Financing Activity | -2,629,000 | -558,000 | -2,312,000 | -78,000 | 3,220,000 |
| Financing Cash Flow | $-11,742,000 | $-8,746,000 | $-8,364,000 | $-5,164,000 | $-14,278,000 |
| Exchange Rate Effect | -298,000 | 16,000 | -160,000 | -126,000 | 100,000 |
| Beginning Cash Position | 13,393,000 | 13,393,000 | 13,393,000 | 13,393,000 | 7,517,000 |
| End Cash Position | 11,459,000 | 13,609,000 | 7,903,000 | 9,469,000 | 13,393,000 |
| Net Cash Flow | $-1,934,000 | $216,000 | $-5,490,000 | $-3,924,000 | $5,876,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 17,619,000 | 13,426,000 | 7,140,000 | 2,265,000 | 14,458,000 |
| Capital Expenditure | -1,366,000 | -808,000 | -487,000 | -227,000 | -1,060,000 |
| Free Cash Flow | 16,253,000 | 12,618,000 | 6,653,000 | 2,038,000 | 13,398,000 |